Protai is at the forefront of drug discovery, utilizing a unique platform that integrates proteomics and machine learning to enhance the understanding of biological systems at the protein level. Their approach focuses on creating a comprehensive proteomic atlas by harmonizing extensive clinical datasets, which allows for the identification of specific causal targets associated with diseases. This foundational work enables Protai to simulate disease dynamics accurately, facilitating the discovery of novel drug targets and mechanisms of action. The company emphasizes a precision medicine approach, aiming to streamline the drug development process through its AIMS™ platform, which is designed to prioritize emerging drug targets effectively.

The technology employed by Protai leverages advanced mass spectrometry techniques to analyze a vast array of proteo-forms, including post-translational modifications and protein interactions. By employing machine learning models, Protai can identify and quantify these proteo-forms, which are critical for understanding the complexities of disease. Their target prioritization engine further refines this process by evaluating the most promising candidates for validation, combining insights from biology, chemistry, and computational methods. This multidisciplinary strategy positions Protai to discover and characterize drug candidates that can significantly impact the treatment of complex diseases.

Israel

Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.

Protai

Company Details